Bevacizumab vs. triamcinolone

Ophthalmology. 2010 Apr;117(4):855-855.e2. doi: 10.1016/j.ophtha.2009.10.012.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Cataract / chemically induced
  • Disease Progression
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Macula Lutea / pathology
  • Macular Edema / drug therapy*
  • Macular Edema / etiology
  • Macular Edema / physiopathology
  • Male
  • Pilot Projects
  • Retreatment
  • Treatment Outcome
  • Triamcinolone Acetonide / therapeutic use*
  • Uveitis / complications
  • Uveitis / drug therapy
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Triamcinolone Acetonide